ClinicalTrials.gg
RecruitingNCT03315676Updated Sep 21, 2021

Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers

A Phase 2 interventional study of Oral Bonoprazan and Oral Esomeprazol in Gastrointestinal Erosions and/or Ulcers, sponsored by Shinshu University. Recruiting at 1 site in Japan. Open to participants aged 20 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Shinshu University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2022, 3 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2017; still recruiting 9 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
20 Years to 99 Years
Sex
All
01

Study summary

The aim of this study is to collect the data of clinical efficacy and safety after the usage of bonoprazon and esomeprazole when the patients take NSAIDs more than 2 weeks and have gastrointestinal symptoms who have had gastrointestinal erosions and/or ulcers in the past.

02

Conditions studied

  • Gastrointestinal Erosions and/or Ulcers

Browse trials for

03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 60 are open to participants now.

This study's planned enrollment of 124 is above the median of 65 across 291 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

Shinshu University is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of NSAIDs-induced gastrointestinal Erosions and/or Ulcers who want to take Bonoprazan or Esomeprazole

Exclusion criteria

Exclusion Criteria:

  • Patients allergic to Bonoprazan or Esomeprazole
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
124 participants (estimated)

Study arms

  • Active comparator
    Oral Bonoprazan

    Daily intake of Bonoprazan

    Drug: Oral Bonoprazan

  • Active comparator
    Oral Esomeprazol

    Daily intake of Esomeprazol

    Drug: Oral Esomeprazol

Interventions

  • DrugOral Bonoprazan

    To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers

  • To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers

06

What researchers measure

Primary outcomes

  1. Number of participants with healing of gastrointestinal erosions and/or ulcers using major forceps

    Time frame: Change from Baseline Gastrointestinal erosions and/or ulcers at 2 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2017 (actual). Primary completion is estimated for Nov 2022, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2017
First posted
Oct 20, 2017
StartActual
Nov 1, 2017
Primary completionEst.
Nov 21, 2022
CompletionEst.
Sep 4, 2025
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03315676
Lead sponsor
Shinshu University
Responsible party
Yukio Nakamura (Lecturer at Shinshu University School of Medicine, Shinshu University) — Principal investigator
First posted
Oct 20, 2017
Start date
Nov 1, 2017
Primary completion
Nov 21, 2022 (estimated)
Completion
Sep 4, 2025 (estimated)
Last update
Sep 21, 2021

Study contacts

Yukio Nakamura, MD, PhD
Contact
yxn14@aol.jp
+81-263-37-2659

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion